Eli Lilly & Co. agreed to buy AtaiBeckley Inc. for as much as $3.8 billion, underscoring growing interest from large drugmakers in the once-fringe area of psychedelic medicine.
Lilly will pay $6.75 a share in cash plus as much as another $2.50 a share if drug-development milestones are met, according to a statement Thursday. The base price is 26% above where AtaiBeckley shares closed Wednesday. The announcement confirms a report by Bloomberg News that the companies were nearing a deal.
Shares of New York-based AtaiBeckley have more than doubled over the past year through Wednesday’s close. They jumped 32% at 9:35 a.m. on Thursday. Lilly fell 0.9%.
Bloomberg previously reported that AtaiBeckley was exploring options for a sale or partnership for its flagship drug, known as BPL-003. The medicine is a fast-acting nasal spray for treatment-resistant depression.
The deal deepens Lilly’s longstanding presence in neuroscience, an area where the company helped transform the treatment of depression with Prozac three decades ago.
While the Indianapolis-based drugmaker is now best known for its blockbuster obesity and diabetes medicines, it’s continued to invest in neuroscience, including treatments for Alzheimer’s disease and non-addictive pain drugs. Lilly has been eyeing the psychedelics space for a while, according to people familiar with the company’s thinking who requested anonymity discussing non-public matters.
The deal comes at a pivotal moment for psychedelic medicine. After years on the fringes of drug development, the field has been buoyed by the success of Johnson & Johnson’s Spravato, promising trial results and recent support from the Trump administration. Bloomberg Intelligence analysts say the psychedelic-treatment market could reach $7 billion in sales by 2032.
New Era
AtaiBeckley is one of several companies poised to usher in this new era. Besides treatment-resistant depression, the company, founded by German entrepreneur Christian Angermayer and backed by billionaire Peter Thiel, is developing drugs for social anxiety disorder.
In mid-stage studies, patients taking AtaiBeckley’s lead drug experienced meaningful improvements in depressive symptoms within just two days of a single dose, with benefits lasting up to eight weeks. The drug received Breakthrough Therapy designation from the US Food and Drug Administration.
Doctors, and the company, say one of BPL-003’s key benefits is its shorter treatment time. The drug’s psychedelic experience lasts roughly one to two hours, while a rival compound from Compass Pathways Plc may require patient monitoring for up to eight hours. GH Research Plc is developing a similar treatment.
“We really wanted something that was going to be patient friendly and doctor friendly,” AtaiBeckley Chief Executive Officer Srinivas Rao said in a recent interview at Bloomberg’s New York office. “Something that would drag and drop into the Spravato paradigm.”
Other companies working on psychedelics include Definium Therapeutics Inc., which is studying a promising LSD-based treatment for major depressive disorder, and AbbVie Inc.
Definium Therapeutics rose 4.2% in early trading Thursday on the Lilly announcement, while other companies involved in psychedelics also gained. Compass climbed 2.9%, Cybin Inc. advanced 8.7% and GH Research gained 8.4%.
Goldman Sachs Group Inc. advised Lilly on the deal, while AtaiBeckley worked with Moelis & Co. and Centerview Partners. Citigroup Inc. advised the AtaiBeckley board.
The upfront cash payment in the acquisition amounts to about $2.8 billion, with AtaiBeckley shareholders to receive another roughly $1 billion if all milestones are met, according to the statement.
Angermayer, in a post on X, said that when he started contemplating bringing psychedelics back into mainstream medicine in 2014, “it was widely seen as a crazy idea with virtually no chance of success. Today, psychedelic medicine feels almost inevitable. Back then, it was anything but.”
A message from Advisor Perspectives and VettaFi: Discover something new! Click here to register for our upcoming webcasts.
Bloomberg News provided this article. For more articles like this please visit
bloomberg.com.
Read more articles by Eyk Henning, Madison Muller
